{"commentary":{"count":67,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":40,"youtube":17,"podcast":10},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02926196\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"A-Brave","nct_id":"NCT02926196","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=a-brave-nct02926196. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"A-Brave","arms":[{"description":"Avelumab 10 mg/kg I.V. q2w for 1 year (52 weeks)","label":"Arm Avelumab","type":"EXPERIMENTAL"},{"description":"Observation as per guidelines","label":"Arm Observation","type":"NO_INTERVENTION"}],"collaborators":["University of Padova","Dipartimento di scienze chirurgiche, Oncologiche e Gastroenterologiche"],"completion_date":{"date":"2025-10-09","type":"ACTUAL"},"conditions":["Triple Negative Breast Neoplasms"],"enrollment":{"count":474,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"MSB0010718C","type":"DRUG"}],"last_update":"2025-12-12","lead_sponsor":"Istituto Oncologico Veneto IRCCS","official_title":"Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial. Sponsor: Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Università di Padova","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease free survival","timeFrame":"Up to 5 years after randomization"},{"measure":"Disease free survival in PD-L1-positive patients","timeFrame":"Up to 5 years after randomization"}],"references":[],"start_date":{"date":"2016-06-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab","url":"https://clinicaltrials.gov/study/NCT02926196"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/a-brave-nct02926196"}